Cipla News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Cipla Ltd.

04 Sep 2026

1365.30

0.16%

Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field

Business Line

Cipla stock trades at 1,388, down 0.48% or 6.70 from its previous close of 1,394.70

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

04 Sep 2026

1365.30

0.16%

Cipla partners with Qilu to license, supply Keytruda biosimilar in US

Business Standard

Drug major Cipla Ltd on Thursday said its wholly owned subsidiary, Invagen Pharmaceuticals Inc, has entered into a strategic partnership with Qilu Pharmaceutical for the licensing and supply of a biosimilar to the cancer drug Keytruda in the United States. The product, QL2107, is a biosimilar to pembrolizumab (Keytruda) and aims to improve access to advanced therapies for cancer patients while lowering treatment costs, Cipla said in a regulatory filing. Under the agreement, Qilu will be responsible for the development, regulatory registration, and supply of the product, while Cipla will leverage its commercial presence to market the asset in the US. "This partnership reflects Cipla's confidence in the long-term potential of biosimilars and supports our strategy to build a strong oncology-focused portfolio," said Achin Gupta, Managing Director and Global Chief Executive Officer, Cipla. Hanchang Zhang, General Manager of Qilu Pharmaceutical, said, "We are pleased to establish this ..

Number of FII/FPI investors decreased from 964 to 917 in Jun 2026 qtr

Cipla's US subsidiary partners with Qilu for Keytruda biosimilar

Business Line | 04 Sep 2026

Cipla Ltd.

03 Sep 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''

pdf

Cipla Ltd.

03 Sep 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Notice To Shareholders And Creditors In Accordance With NCLT Order Dated …

BSE India

Please find enclosed disclosure

pdf

Cipla Ltd.

02 Sep 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached newspaper publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

pdf

Cipla Ltd.

31 Aug 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Please find enclosed press release titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)"

pdf

Cipla Ltd.

29 Aug 2026

1365.30

0.16%

Maharashtra FDA cancels Cipla's Pune unit licence; company contests order

Business Line

The drugmaker said the order does not allege concerns over product safety, quality or efficacy, or indicate any patient safety issue

Cipla Ltd. has an average target of 1527.75 from 8 brokers.

Maharashtra FDA cancels Cipla C&F licences in Pune; firm contests order

Business Standard | 28 Aug 2026

Cipla Ltd.

28 Aug 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, …

BSE India

Please find enclosed disclosure.

pdf

Cipla Ltd.

27 Aug 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Restructuring

BSE India

Please find enclosed disclosure.

pdf

Cipla Ltd.

27 Aug 2026

1365.30

0.16%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meeting with the Company.

pdf

Is Cipla Ltd. worth buying?

650 Votes:

Buy 75.85%

Sell 13.54%

Hold 10.62%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf